Abstract. Asthma is a serious health problem and one of the most common causes of morbidity and mortality worldwide. The therapy of asthma has evolved significantly during the last two decades attributing to better understanding of pathogenesis. According to asthma therapy guidelines, inhaled corticosteroids and long acting beta agonist are recommended as the corner stone of moderate to severe persistent asthma therapy. Immunotherapy is recommended as an adjuvant therapy for allergic asthma. Recently, phosphodiesterase 4 inhibitor and bronchiothermoplasty therapy are approved for asthma. We reviewed the systemic side effects of long term use of inhaled corticosteroids, safety of long acting beta 2 -agonist, clinical experience of immunotherapy focusing on anti-IgE therapy and specific immunotherapy, clinical evidence for use of phosphodiesterase 4 inhibitor and bronchiothermoplasty. Key words: asthma, therapy, inhaled corticosteroids, LABA, PDE4 inhibitor, specific immunotherapy, bronchiothermoplasty.